CEL-SCI (CVM) said Wednesday that it has completed its Breakthrough Medicine Designation application to the Saudi Food and Drug Authority for its Multikine investigational cancer medicine.
The company said it expects its prospective Saudi partner to formally submit the application to the Saudi regulator on its behalf in the coming weeks.
The company said Multikine would immediately become available for patient access and reimbursement under the regulator's Breakthrough Medicine Designation program, which typically takes 60 days for an application response.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.